Anticancer Therapy Flashcards
what are the stages of the commonly used/simple staging system
0 - primary site/no invasion to surrounding tissues
1 - small or localized/no invasion to surrounding tissues
2 - larger than I/no invasion to surrounding tissues
3 - increased size, lymph nodes metastasis starting to invade surrounding tissues
4 - metastasized to other organs
what are the stages of the TNM staging system
T (primary tumor) - 1 = small, 4 = large
N (lymph nodes) - 0 = no LN meastasis 3 = significant LN cancer presence
M (metastasis) - 0 = no metastasis or 1 = metastasised to other organs
this is involves descrpitive differences of normal and malignant cells under the microscope
cancer grades (severity of cancer)
list the three grades of cancer
1 - similar, slow growth
2 - different and growing fast
4 - very different and growing very fast
what are some factors that can lead to cancer
- age!!!!!!
- genetics
- environment (pollution, food, smoking , lifestyle, etc)
this is a mass of cells (Tumor) that lacks the ability to invade neighbouring tissues or metastasize
benign tumor
cancer = malignant tumors + _________
leukemia
what are the 3 factors that contribute to the probability of cancer (P)?
P = a x b x e
e = probability of oncogenic genes (~ equal for everyone)
a = # of cells division
- aging increased cell dividion
- organ/tissue damage and repair (sun burn, smoking, polluted food, viral infections e.x. HPV, HBV)
b = # of mutations for each cell division
- mainly genetic (e.g. brac1 increases risk of breast and ovarian cancer by 100 fold)
what are the 3 ways cancer leads to death?
- excessive growth leads to organ failure
- brain tumors, lung cancer, leukemia - metastasis to vital organ
- brain, bone, lung, liver (BBLL) - cachexia
- loss of fat and muscles
- sepsis (infection -> inflammation -> multiple organ failure)
what are some challenges of cancer treatment
- narrow windows of therapuetic index
- kills normal cells and tissues - heterogeneity of targeted genes (e.g. an ALK inhibitor is only effective in ~1% of lung cancer patients)
- multi-drug resistance